锌用于镰状细胞贫血儿童感染预防:一项随机双盲安慰剂对照试验
在乌干达1.00-4.99岁镰状细胞贫血(SCA)儿童中开展随机双盲安慰剂对照试验,252例入组,124例每日补锌10 mg、126例安慰剂,持续12个月。补锌未降低方案定义的严重或侵袭性感染发生率(每100人年282 vs 270,发生率比1.04,95%CI 0.81-1.32,p=0.78),41%补锌儿童退出时仍缺锌。
要点
- 每日10 mg锌持续12个月未预防乌干达SCA儿童的严重或侵袭性感染。
- 补锌组与安慰剂组感染发生率无差异(每100人年282 vs 270,发生率比1.04,95%CI 0.81-1.32,p=0.78)。
- 补锌12个月后血清锌升高,但退出时41%仍缺锌(<65 μg/dL)。
核心结论
- 每日10 mg锌补充12个月未预防乌干达SCA儿童的严重或侵袭性感染,且许多补锌儿童仍缺锌。
- 最佳锌剂量及锌在预防SCA卒中或死亡中的作用需进一步研究。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入乌干达1.00-4.99岁SCA儿童252例,124例每日补锌10 mg、126例安慰剂,持续12个月。
- 主要结局为方案定义的严重或侵袭性感染发生率。
- 试验注册号NCT03528434。
主要发现
- 补锌组与安慰剂组严重或侵袭性感染发生率无差异:每100人年282 vs 270,发生率比1.04(95%CI 0.81-1.32,p=0.78),校正羟基脲治疗。
- 两组严重不良事件或SCA相关事件发生率无差异。
- 补锌12个月后血清锌升高,但退出时41%仍缺锌(<65 μg/dL)。
- 事后分析中,补锌组卒中或死亡发生较低:校正风险比0.22(95%CI 0.05-1.00),p=0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 事后分析中卒中或死亡结果校正风险比0.22(95%CI 0.05-1.00),p=0.05,置信区间上限达1.00。
- 最佳锌剂量及锌在预防SCA卒中或死亡中的作用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data from small clinical trials in the United States and India suggest zinc supplementation reduces infection in adolescents and adults with sickle cell anemia (SCA), but no studies of zinc supplementation for infection prevention have been conducted in children with SCA living in Africa. We conducted a randomized double-blind placebo-controlled trial to assess zinc supplementation for prevention of severe or invasive infections in Ugandan children 1.00-4.99 years with SCA. Of 252 enrolled participants, 124 were assigned zinc (10 mg) and 126 assigned placebo once daily for 12 months. The primary outcome was incidence of protocol-defined severe or invasive infections. Infection incidence did not differ between treatment arms (282 vs. 270 severe or invasive infections per 100 person-years, respectively, incidence rate ratio of 1.04 [95% confidence interval (CI), 0.81, 1.32, p=0.78]), adjusting for hydroxyurea treatment. There was also no difference between treatment arms in incidence of serious adverse events or SCA-related events. Children receiving zinc had increased serum levels after 12-months, but at study exit, 41% remained zinc deficient (<65 μg/dL). In post-hoc analysis, occurrence of stroke or death was lower in the zinc treatment arm (adjusted hazard ratio (95% CI), 0.22 (0.05, 1.00); p=0.05). Daily 10 mg zinc supplementation for 12 months did not prevent severe or invasive infections in Ugandan children with SCA, but many supplemented children remained zinc deficient. Optimal zinc dosing and the role of zinc in preventing stroke or death in SCA warrant further investigation. This trial was registered at clinicaltrials.gov as #NCT03528434.
引用
- Namazzi R, Opoka R, Conroy AL, et al. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Adv. 2023. PMID: 36735400. doi:10.1182/bloodadvances.2022008539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。